These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 1834727)

  • 1. Transdermal estradiol with oral progestin: biological and clinical effects in younger and older postmenopausal women.
    Bellantoni MF; Harman SM; Cullins VE; Engelhardt SM; Blackman MR
    J Gerontol; 1991 Nov; 46(6):M216-22. PubMed ID: 1834727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of progestin-opposed transdermal estrogen administration on growth hormone and insulin-like growth factor-I in postmenopausal women of different ages.
    Bellantoni MF; Harman SM; Cho DE; Blackman MR
    J Clin Endocrinol Metab; 1991 Jan; 72(1):172-8. PubMed ID: 1824707
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the effects of an estradiol-releasing vaginal ring combined with an oral gestagen versus transdermal estrogen combined with a levonorgestrel-releasing IUD: clinical findings and endometrial response.
    Kalogirou D; Antoniou G; Karakitsos P; Kalogirou O; Antoniou D; Giannikos L
    Int J Fertil Menopausal Stud; 1996; 41(6):522-7. PubMed ID: 9010746
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
    Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
    Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with transcutaneous estradiol and oral medroxyprogesterone acetate.
    Pedersen OD; Jensen HK
    Acta Obstet Gynecol Scand; 1992 Dec; 71(8):593-8. PubMed ID: 1336917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of transdermal and vaginal estrogen therapy on markers of postmenopausal estrogen status.
    Gupta P; Ozel B; Stanczyk FZ; Felix JC; Mishell DR
    Menopause; 2008; 15(1):94-7. PubMed ID: 17882008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Short- and long-term effects of hormone replacement therapy (transdermal estradiol vs oral conjugated equine estrogens, combined with medroxyprogesterone acetate) on blood coagulation factors in postmenopausal women.
    Boschetti C; Cortellaro M; Nencioni T; Bertolli V; Della Volpe A; Zanussi C
    Thromb Res; 1991 Apr; 62(1-2):1-8. PubMed ID: 1649497
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of aging and gonadal failure on the hypothalamic-pituitary axis in women.
    Santoro N; Banwell T; Tortoriello D; Lieman H; Adel T; Skurnick J
    Am J Obstet Gynecol; 1998 Apr; 178(4):732-41. PubMed ID: 9579435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic studies on low dose estradiol 17 beta administered orally to postmenopausal women.
    Sipinen S; Lähteenmäki P; Luukkainen T
    Acta Obstet Gynecol Scand; 1980; 59(2):149-53. PubMed ID: 6773291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Different hepatobiliary effects of oral and transdermal estradiol in postmenopausal women.
    Van Erpecum KJ; Van Berge Henegouwen GP; Verschoor L; Stoelwinder B; Willekens FL
    Gastroenterology; 1991 Feb; 100(2):482-8. PubMed ID: 1898652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of estradiol vaginal cream in postmenopausal women.
    Dickerson J; Bressler R; Christian CD; Hermann HW
    Clin Pharmacol Ther; 1979 Oct; 26(4):502-7. PubMed ID: 226306
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women.
    Mandel FP; Geola FL; Meldrum DR; Lu JH; Eggena P; Sambhi MP; Hershman JM; Judd HL
    J Clin Endocrinol Metab; 1983 Jul; 57(1):133-9. PubMed ID: 6304131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
    Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
    Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
    de Greef WJ; Dullaart J; Zeilmaker GH
    J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of postmenopausal estrogen/progestin replacement therapy on LDL particles; comparison of transdermal and oral treatment regimens.
    Lahdenperä S; Puolakka J; Pyörälä T; Luotola H; Taskinen MR
    Atherosclerosis; 1996 May; 122(2):153-62. PubMed ID: 8769679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of postmenopausal osteoporosis with transdermal estrogen.
    Lufkin EG; Wahner HW; O'Fallon WM; Hodgson SF; Kotowicz MA; Lane AW; Judd HL; Caplan RH; Riggs BL
    Ann Intern Med; 1992 Jul; 117(1):1-9. PubMed ID: 1534476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration.
    De Lignieres B; Basdevant A; Thomas G; Thalabard JC; Mercier-Bodard C; Conard J; Guyene TT; Mairon N; Corvol P; Guy-Grand B
    J Clin Endocrinol Metab; 1986 Mar; 62(3):536-41. PubMed ID: 3080464
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate.
    Pang SC; Greendale GA; Cedars MI; Gambone JC; Lozano K; Eggena P; Judd HL
    Fertil Steril; 1993 Jan; 59(1):76-82. PubMed ID: 8419226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of transdermal to oral estradiol administration on hormonal and hepatic parameters in women with premature ovarian failure.
    Steingold KA; Matt DW; DeZiegler D; Sealey JE; Fratkin M; Reznikov S
    J Clin Endocrinol Metab; 1991 Aug; 73(2):275-80. PubMed ID: 1906893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
    Lemay A; Faure N; Labrie F; Fazekas AT
    Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.